Boehringer Ingelheim India launches VAXXITEK® HVT + IBD, globally acclaimed single shot poultry vaccine
o VAXXITEK® HVT + IBD provides life-long immunity against Infectious Bursal Disease and Marek’s Disease
o It is the first vector vaccine launched in the avian market
o VAXXITEK® HVT + IBD is available in 100 countries; more than 130 billion birds vaccinated so far
India, 26 May 2021
Boehringer Ingelheim India today announced the launch of its poultry vaccine VAXXITEK® HVT+IBD. An innovative recombinant vaccine, VAXXITEK® HVT+IBD is a single shot vaccine, ensuring life-long protection for all types of production chickens, namely broiler, layer and breeder.
Designed to build and strengthen a stronger immune foundation in poultry, the vaccine enables better flock health and performance. VAXXITEK® HVT+IBD protects against two major immuno suppressive diseases – IBD (Infectious Bursal Disease) and Marek’s Disease, both of which are known to cause significant losses to poultry businesses.
First launched in Brazil, VAXXITEK® HVT+IBD is now available in 100 countries worldwide. With over 130 billion birds vaccinated globally, this is the first vector vaccine launched in the avian market. As the flagship poultry product of Boehringer Ingelheim, VAXXITEK® HVT + IBD is the largest selling poultry vaccine globally in terms of revenue, contributing close to 26 percent of sales in the poultry franchise globally. In India, the poultry vaccine market accounts for around USD 120mn.
Vani Manja, Managing Director, Boehringer Ingelheim India said “With the introduction of VAXXITEK® HVT+IBD, we bring a simplified and effective solution to the Indian poultry market, while providing producers with the flexibility and expected protection against two avian diseases in one product. An innovative single-dose recombinant vaccine, VAXXITEK® HVT+IBD eliminates the need for any additional field vaccination. With our holistic solutions approach, veterinarians and poultry producers are assured of vaccination process convenience and improved performance of the flock.”
Boehringer Ingelheim Animal Health
The lives of animals and humans are interconnected in deep and complex ways. We know that when animals are healthy, humans are healthier too. Across the globe, our 10,000 employees are dedicated to delivering value through innovation, thus enhancing the well-being of both.
Respect for animals, humans and the environment are at the heart of what we do. We develop solutions and provide services to protect animals from disease and pain. We support our customers in taking care of the health of their animals and protect our communities against life- and society-threatening diseases.
Boehringer Ingelheim Animal Health is the second largest animal health business in the world, with net sales of 4.1 billion euros in 2020 and presence in more than 150 countries. For more information visit: www.boehringer-ingelheim.com/animal-health/overview.
Boehringer Ingelheim is working on breakthrough therapies that improve the lives of humans and animals. As a leading research-driven biopharmaceutical company, the company creates value through innovation in areas of high unmet medical need. Founded in 1885 and family-owned ever since, Boehringer Ingelheim takes a long-term perspective. Around 52,000 employees serve more than 130 markets in the three business areas, Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing. Learn more at www.boehringer-ingelheim.com
Established in 2003, Boehringer Ingelheim India, manages the India and the neighboring markets operations of the global enterprise. The Company enables access to innovator products as part of its Human Pharma and Animal Health businesses. The focus Human Pharma therapy areas include diabetes, cardiovascular and respiratory conditions. www.boehringer-ingelheim.in